With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies – STAT
STAT |
With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies
STAT n the latest twist in the immunotherapy market, Merck (MRK 1) disclosed that its Keytruda cancer medicine helped previously untreated lung cancer patients live longer than chemotherapy in a late-stage trial, which may solidify its position as the … Merck eyes best day since 2016, gains help fuel pharma rallyFinancial Times Key Keytruda data drives Merck & Co up by 5%The Pharma Letter This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock SoaringFortune CNBC all 131 news articles » |
|
Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy
Market Realist In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy that includes SB-525, which is one of Sangamo Therapeutics’ four lead product candidates. This collaboration is highly synergistic, as it … Zacks Premium Investment Service – Zacks.comZacks Sangamo Therapeutics, Inc. – SGMO – Stock Price Today – ZacksZacks |
Pueblo Chieftain |
Seattle man is first adult to get new gene therapy for vision
Pueblo Chieftain So Willis checked in with his eye doctor late last year, setting in motion a train of events that culminated March 20 at Children’s Hospital Los Angeles (CHLA), when he became the first adult to undergo the original gene therapy approved in the U.S … |
Community Impact Newspaper |
Lonza to unveil world’s largest dedicated cell/gene therapy manufacturing facility in Pearland
Community Impact Newspaper The Swiss biomedical firm Lonza will officially unveil its manufacturing plant in Pearland’s Lower Kirby district, 14905 Kirby Drive, on April 10. The company says its Pearland site will develop cell and gene therapies from concept, through pre … |
mySanAntonio.com |
Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases
mySanAntonio.com It’s been a big couple of years for gene therapies. In December 2017, the FDA approved the first gene therapy, made by Spark Therapeutics, which is used to treat a hereditary form of blindness. Earlier in the year, the FDA approved the first cell … |
Barron’s |
Why the Deal for AveXis Is a Powerful Vote for Replacement Gene …
Barron’s Novartis’s $8.7 billion deal to buy AveXis, one of the leaders in replacement gene therapy, amounts to a strong endorsement of the developing biotechnology. It also looks bullish for Regenxbio, which makes the viral delivery mechanism for AveXis’s … How a Rockville company benefits from Novartis’ $8.7B purchase of a Chicago biotechWashington Business Journal Analyst: AveXis M&A Could Support Interest In RegenxbioBenzinga Zacks Premium Investment Service – Zacks.comZacks SEC.gov all 47 news articles » |